These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 15690335)

  • 21. DNA ploidy analysis of pleural mesotheliomas: its usefulness for their distinction from lung adenocarcinomas.
    Esteban JM; Sheibani K
    Mod Pathol; 1992 Nov; 5(6):626-30. PubMed ID: 1369798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
    Sherman ME; Mark EJ
    Arch Pathol Lab Med; 1990 Aug; 114(8):845-51. PubMed ID: 2375659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions.
    Croonen AM; van der Valk P; Herman CJ; Lindeman J
    Lab Invest; 1988 Jun; 58(6):725-32. PubMed ID: 3288807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of cytokeratin MNF116 and vimentin in pleural serous effusions.
    Mocanu L; Cîmpean AM; Raica M
    Rom J Morphol Embryol; 2007; 48(3):291-4. PubMed ID: 17914498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
    Illei PB; Ladanyi M; Rusch VW; Zakowski MF
    Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
    Deniz H; Kibar Y; Güldür ME; Bakir K
    Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
    Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
    Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma.
    Shin HJ; Shin DM; Tarco E; Sneige N
    Cancer; 2003 Aug; 99(4):233-9. PubMed ID: 12925985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Routine DNA cytometry of benign and malignant pleural effusions by means of the remote quantitation server Euroquant: a prospective study.
    Kayser K; Blum S; Beyer M; Haroske G; Kunze KD; Meyer W
    J Clin Pathol; 2000 Oct; 53(10):760-4. PubMed ID: 11064669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The malignancy grading method is not a reliable assessment of malignancy in mesothelioma.
    Tierney G; Wilkinson MJ; Jones JS
    J Pathol; 1990 Mar; 160(3):209-11. PubMed ID: 2335801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoperoxidase staining of malignant cells in pleural effusions.
    Pastormerlo M
    Pathologica; 1990; 82(1080):421-5. PubMed ID: 2284143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
    Kobzik L; Antman KH; Warhol MJ
    Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA analysis by flow cytometry in malignant pleural mesothelioma: relationship to histology and survival.
    Dazzi H; Thatcher N; Hasleton PS; Chatterjee AK; Lawson RA
    J Pathol; 1990 Sep; 162(1):51-5. PubMed ID: 2231193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
    Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
    J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Flow cytometry and malignant pleural mesotheliomas. Value in the histologic and cytologic diagnosis].
    Courtin P; Foulet A; Sartiaux C; Gosselin B
    Arch Anat Cytol Pathol; 1993; 41(5-6):229-31. PubMed ID: 8135584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
    Loveland P; Christie M; Hammerschlag G; Irving L; Steinfort D
    Intern Med J; 2018 Nov; 48(11):1318-1324. PubMed ID: 29869427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis of pleural malignant mesothelioma in life--a practical approach.
    Whitaker D; Shilkin KB
    J Pathol; 1984 Jul; 143(3):147-75. PubMed ID: 6379132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relative DNA content and cycle distribution of cells in pleural effusions studied by flow-cytometry].
    Shen C; Ye YQ; Lou WT
    Zhonghua Jie He He Hu Xi Za Zhi; 1994 Apr; 17(2):90-2, 126. PubMed ID: 7994775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.